EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24‐week real‐world study

Teppei Hagino iD, Marina Onda, Hidehisa Saeki iD, Eita Fujimoto, Naoko Kanda iD

The Journal of Dermatology · 2024-12 · 51 (12) · 1658-1664

DOI: 10.1111/1346-8138.17427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 12.08.2024. Verfasst von Teppei Hagino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Psoriasis, Quality of Life, Scalp Dermatoses, Nail Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a complex, chronic inflammatory skin disease that significantly impacts patients' quality of life (QOL), especially in cases of genital, nail, and scalp psoriasis. Bimekizumab is an inhibitor of interleukin (IL)‐17A and IL‐17F and used for the treatment of psoriasis. The aim of this retrospective study was to evaluate the effectiveness of bimekizumab through in treating genital, nail, and scalp lesions with psoriasis over 24 weeks. The study was conducted from May 2022 and February 2024 on 52 psoriasis patients treated with bimekizumab. The therapeutic effects of bimekizumab were evaluated by the achievement of Physician's Global Assessment (PGA) rates of 0/1 on the genitals (genital‐PGA), fingernails (PGA‐F), scalp‐specific PGA (ss‐PGA), static PGA (sPGA), and the Dermatology Life Quality Index (DLQI) at weeks 4, 16, and 24. Bimekizumab treatment significantly improved genital, nail, and scalp lesions with psoriasis. At week 24, the achievement rate of genital‐PGA 0/1, PGA‐F 0/1, ss‐PGA 0/1 was 96.2%, 66.7%, or 93.9%, and that of sPGA 0/1 or DLQI 0/1 was 93.9% or 83.3%, respectively. Bimekizumab was effective for genital, nail, and scalp lesions with psoriasis, difficult‐to‐treat lesions, and simultaneously improved QOL in a real‐world clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisQuality of LifeScalp DermatosesNail DiseasesHumansMaleFemaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeAntibodies, Monoclonal, HumanizedAgedSeverity of Illness IndexGenital Diseases, FemaleGenital Diseases, MaleDermatologic Agents

Stichwörter der Autor:innen

bimekizumabgenitalnailpsoriasisscalp

Substanzen

bimekizumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino, Hidehisa Saeki, Naoko Kanda

Zitieren

APA

Hagino, T., Onda, M., Saeki, H., Fujimoto, E., & Kanda, N. (2024). Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24‐week real‐world study. The Journal of Dermatology, 51(12), 1658-1664. https://doi.org/10.1111/1346-8138.17427

Vancouver

Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24‐week real‐world study. The Journal of Dermatology. 2024;51(12):1658-1664. doi:10.1111/1346-8138.17427

BibTeX
@article{Hagino2024,
  author = {Hagino, Teppei and Onda, Marina and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
  title = {Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24‐week real‐world study},
  journal = {The Journal of Dermatology},
  year = {2024},
  volume = {51},
  number = {12},
  pages = {1658--1664},
  doi = {10.1111/1346-8138.17427}
}
Kostenlos starten →